Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study

• Published in: Pharmaceutics Vol. 13; no. 10; p. 1668
• Main Authors: Persano, Stefano, Vicini, Francesco, Poggi, Alessandro, Fernandez, Jordi Leonardo Castrillo, Rizzo, Giusy Maria Rita, Gavilán, Helena, Silvestri, Niccolo, Pellegrino, Teresa
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 12.10.2021; MDPI
• Subjects: Adaptive immunity; Antigens; Brain cancer; Cancer therapies; Chemotherapy; Cytotoxicity; Fever; glioblastoma; Heat; Heat shock proteins; Hyperthermia; immunogenic cell death; Immunotherapy; innate immunity; Ligands; Lymphocytes; macrophages; Magnetic fields; magnetic hyperthermia; Nanoparticles; natural killer; Polyethylene glycol; Radiation therapy; Tumors
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics13101668

Cancer immunotherapies have been approved as standard second-line or in some cases even as first-line treatment for a wide range of cancers. However, immunotherapy has not shown clinically relevant success in glioblastoma (GBM). This is principally due to the brain’s “immune-privileged” status and the peculiar tumor microenvironment (TME) of GBM characterized by a lack of tumor-infiltrating lymphocytes and the establishment of immunosuppressive mechanisms. Herein, we explore a local mild thermal treatment, generated via cubic-shaped iron oxide magnetic nanoparticles (size ~17 nm) when exposed to an external alternating magnetic field (AMF), to induce immunogenic cell death (ICD) in U87 glioblastoma cells. In accordance with what has been observed with other tumor types, we found that mild magnetic hyperthermia (MHT) modulates the immunological profile of U87 glioblastoma cells by inducing stress-associated signals leading to enhanced phagocytosis and killing of U87 cells by macrophages. At the same time, we demonstrated that mild magnetic hyperthermia on U87 cells has a modulatory effect on the expression of inhibitory and activating NK cell ligands. Interestingly, this alteration in the expression of NK ligands in U87 cells upon MHT treatment increased their susceptibility to NK cell killing and enhanced NK cell functionality. The overall findings demonstrate that mild MHT stimulates ICD and sensitizes GBM cells to NK-mediated killing by inducing the upregulation of specific stress ligands, providing a novel immunotherapeutic approach for GBM treatment, with potential to synergize with existing NK cell-based therapies thus improving their therapeutic outcomes.